Safety, tolerability, and pharmacokinetics of SR 49059, A V1A vasopressin receptor antagonist, after repeated oral administration in healthy volunteers

Advances in Experimental Medicine and Biology

Volumn 449, Issue , 1998, Pages 455-465

  Brouard, R ^a   Laporte, V ^a   Serradeil Le Gal, C ^a   Pignol, R ^a   Jang, H ^b   Donat, F ^a   Lockwood, G ^b   Fournie, D ^a   Dreux, F ^a  

^a SANOFI   (France)

^b Sanofi Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECEPTOR SUBTYPE; RELCOVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRADERMAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SKIN BLOOD VESSEL; THROMBOCYTE AGGREGATION; URINE OSMOLALITY; URINE VOLUME; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ADULT; ARGININE VASOPRESSIN; BLOOD PLATELETS; BLOOD PRESSURE; DIURESIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HORMONE ANTAGONISTS; HUMANS; INDOLES; MALE; METABOLIC CLEARANCE RATE; PLACEBOS; PLATELET AGGREGATION INHIBITORS; PYRROLIDINES; RECEPTORS, VASOPRESSIN; REGIONAL BLOOD FLOW; SKIN; VASOPRESSINS;

ANIMALIA;

EID: 0031650048     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4871-3_59     Document Type: Article

References (23)

1. Jard S, Elands S, Schmidt A, Barberis C. (1988): Vasopressin and oxytocin receptors: an overview. In: Imura H, Shizurne K (eds) Progress in Endocrinology. Excerpta medico, Amsterdam, pp 1183-1188.
2. Rosenthal W, Seibold A, Antaramian A, et al. (1992): Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 359: 233-235.
3. Koch KL. (1991): Nausea and vasopressin. Lancet 337: 1133-1134.
4. Akerlund M. (1993): The role of oxytocin and vasopressin in the initiation of preterm and term labour as well as primary dysmenorrhoea. Reg. Peptides 45:187-191.
5. Laszlo FA, Laszlo F Jr, Wied DD. (1991): Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 43: 73-108.
6. Mah SC, Hofbauer KG. (1987): Antagonists of AVP: experimental and clinical applications. Drugs future 12: 1055-1070
7. Yamamura Y, Ogawa H, Chihara T, Konndo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. (1991): OPC-21268, an orally effective, non-peptide vasopressin VI receptor antagonist. Science 252: 572-574.
8. Wagnon J, et al. (1993): The discovery of a new potent selective orally effective non peptide AVP Via receptor antagonist SR 49059. In: Gross D, et al. (eds) Vasopressin. J. Libbey Eurotext, London, pp 619.
9. SerradeiL-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G. (1993): Biochemical and pharmacological properties of SR 49059, a new potent, non-peptide antagonist of rat and human vasopressin Via receptors. J. Clin. Invest. Volume 92, 224-231.
10. Serradeil-Le Gal C, Villanova G, Boulin M, Maffrand JP, Le Fur G. (1995): Effects of SR 49059, a nonpeptide antagonist of vasopressin Via receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits. Fundam. Clin. Pharmacol. 9: 17-24
11. Haslam RJ, Rosson GM. (1972): Aggregation of human blood platelets by vasopressin. Am. J. Physiol. 223: 958-967.
12. Filep J, Rosenkranz B. (1987): Mechanism of vasopresssin-induced platelet aggregation. Thrombosis Res. 45: 7-16.
13. Thibonnier M, Roberts JM. (1985): Characterization of human platelet vasopressin receptors. J. Clin. Invest. 76: 1857-1864.
14. Vittet D, Rondot A, Cantau B, Launay JM, Chevillard C. (1986): Nature and properties of human platelet vasopressin receptors. Biochem. 233: 631-636.
15. Wun t, Paglieroni T, Lachant NA. (1996): Physiologic concentrations of arginine vasopressin activate human platelets in vitro. Brit. J. Haemato. 92(4): 968-972.
16. Born GVR, Cross MJ. (1963): The aggregation of blood platelets. J. Physiol. 168: 178-195.
17. Serradeil Le Gal C, Herbert J, Delisee C, Schaeffer P, Raufaste D, Garcia C, Dol F, Marty E, Maffrand JP, Le Fur G. (1995): Effect of SR 49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells. Am. J. Physiol. 268: H404-H410.
18. Brouard R, Chassard D, Hediard N, Pignol R, Leenhardt AF, Serradeil-Le Gal C, Thiebault J, Kusmierek JJE. (1995): The advantage of surrogate markers during phase I for new exploratory compounds. Application for SR 49059, an orally active V1a vasopressin receptor antagonist. Therapie. 4: 34.
19. Kinter LB, Ilson BE, Caltabianol S, Jorkasky DK, Murphy DJ, Solleveld HA, Rhodes GR, Brooks DP, Algrightson-Winslow CR, Stole RM, Huffman WF. (1991): Antidiuretic hormone antagonism in humans: are there predictors? In Vasopressin. Jard S, Jamison R (eds). Colloque Inserm/John Libbey Eurotext Ltd. 208: 321-329.
20. Goldsmith SR, Francis GS, Cowley AW, Levine B, Cohn JN. (1983): Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1: 1385-1390.
21. Lohmeier TE, Smith MJ Jr, Cowley AW Jr, Manning RD Jr, Guyton AC. (1981): Is vasopressin an important hypertensive hormone ? Hypertension. 3: 416-425.
22. Gavras H, Hatzinikolaou P, North WG, Bresnahan M, Gavras I. (1982): Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension. 4: 400-405
23. Share L, Crofton JT. (1984): The role of vasopressin in hypertension. Federation Proceed. 43: 103-106.